PMID- 21241552
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20110118
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 7
IP  - 4
DP  - 2004 Aug 20
TI  - [Phase II clinical trial of homemade human rh-endostatin in the treatment of 
      patients with stage IIIB-IV non-small cell lung cancer].
PG  - 325-8
LID - 10.3779/j.issn.1009-3419.2004.04.13 [doi]
AB  - BACKGROUND: To evaluate the efficacy and safety of homemade human rh-endostatin 
      (YH-16) combined with NP regimen (vinorelbine+cisplatin) for stage IIIB-IV non 
      small cell lung cancer (NSCLC), and to compare with NP regimen alone. METHODS: 
      Eighteen NSCLC patients were divided into two groups. Group A ( n =9) received 
      YH-16 combined with NP plan. Group B ( n =9) received NP regimen. They were 
      treated with 2 or 3 cycles of chemotherapy. The overall response, time to 
      progression (TTP), quality of life (QOL) and safety were observed. RESULTS: The 
      overall response was 22.2% in group A, and 0% in group B ( P > 0.05). The 
      clinical benefit rate was 100% in group A, and 44.4% in group B ( P < 0.05). 
      There was no significant relationship between response and clinical pathological 
      characteristics of patients ( P > 0.05). The TTP was 178.8+/-70.8 days in group A 
      and 85.4+/-48.2 days in group B ( P < 0.05). The main toxicities of the two groups 
      were hematological toxicities, nausea and vomiting. No significant difference in 
      incidence of toxicity was observed between the two groups ( P > 0.05). 
      CONCLUSIONS: The rh-endostatin combined with NP regimen for NSCLC tends to show a 
      better chemotherapeutic effect and less toxicity than NP regimen alone. It is 
      worthy of extensive clinical trial.
FAU - Shi, Heling
AU  - Shi H
AD  - Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Hospital, 
      Beijing 101149, P.R.China.
FAU - Xu, Liyan
AU  - Xu L
FAU - Liu, Zhe
AU  - Liu Z
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
EDAT- 2004/08/20 00:00
MHDA- 2004/08/20 00:01
CRDT- 2011/01/19 06:00
PHST- 2011/01/19 06:00 [entrez]
PHST- 2004/08/20 00:00 [pubmed]
PHST- 2004/08/20 00:01 [medline]
AID - 10.3779/j.issn.1009-3419.2004.04.13 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2004 Aug 20;7(4):325-8. doi: 
      10.3779/j.issn.1009-3419.2004.04.13.